Aydan Mertoğlu
Research Subjects
Aydan Mertoğlu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Gunseli Balci
SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İZMİR DR. SUAT SEREN GÖĞÜS HASTALIKLARI VE CERRAHİSİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ
4 shared publications - Ali Kadri Çırak
Department of Pulmonology, Izmir Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, University of Health Sciences, 35170 Izmir, Türkiye
2 shared publications - Emel Cireli
Pulmonology, Health Sciences University, Dr Suat Seren Chest Diseases and Surgery Training and Research Hospital, Konak, Turkey
2 shared publications - Yelda Varol
Department of Pulmonology, University of Health Sciences Türkiye, Izmir Faculty of Medicine, Izmir City Hospital, Izmir 35353, Türkiye
2 shared publications Ahmet Yanarateş
Nuclear Medicine, İzmir City Hospital, Izmir, Turkey
1 shared publication- Alev Gurgun
Department of Chest Diseases Ege University Faculty of Medicine İzmir Türkiye
1 shared publication
Latest Publications
- Open Access
- 24 February 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-9
Comparison of prognosis between epidermal growth factor mutation positive and negative groups in lung adenocarcinoma patients with brain metastases
Introduction: Brain metastasis (BM) in non-small cell lung cancer (NSCLC) is still an important reason for morbidity and mortality despite the advances in cancer treatment. Using tyrosine kinase inhibitors against epidermal growth factor receptors (EGFR) mutations revolutionized NSCLC treatment. We investigated whether the presence of EGFR mutation influences survival in patients with lung adenocarcinoma with BM. Material and methods: The data of the patients with pathological diagnoses of NSCLC and BM at tertiary hospitals were analyzed retrospectively in terms of survival. A total of 2554 patients diagnosed with NSCLC pathologically between 01 January 2010 and 01 January 2021 were identified. After the exclusion of patients with a lack of data, unknown EGFR mutation status, no brain metastasis, and additional malignancy 336 patients were included in the study. Results: It was found that EGFR ( +) patients were more female dominant (48.6% vs 13.3% p < 0.0001) and were have less history of smoking (47.2% vs 87.1%, p < 0.0001) and were better survival (79.2% vs 92.8%). We found negativity of EGFR increased death risk by 1.700 times (95% CI 1.323–2.183, p < 0.0001) in univariate analysis and by 1.724 times (95% CI 1.251–2.377, p = 0.0001) in multivariate analysis. When overall survivals were compared estimated overall survival time of EGFR ( −) patients was 10.088 (95% CI 8.571–11.606) months and of EGFR ( +) patients was 11.829 months (95% CI 10.336–13.323) (p < 0.001). Conclusion: EGFR positivity was associated with survival. Also, survival was significantly longer in EGFR-positive patients with brain metastases diagnosed with NSCLC.
- 24 February 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-9
Open AccessComparison of prognosis between epidermal growth factor mutation positive and negative groups in lung adenocarcinoma patients with brain metastases
Introduction: Brain metastasis (BM) in non-small cell lung cancer (NSCLC) is still an important reason for morbidity and mortality despite the advances in cancer treatment. Using tyrosine kinase inhibitors against epidermal growth factor receptors (EGFR) mutations revolutionized NSCLC treatment. We investigated whether the presence of EGFR mutation influences survival in patients with lung adenocarcinoma with BM. Material and methods: The data of the patients with pathological diagnoses of NSCLC and BM at tertiary hospitals were analyzed retrospectively in terms of survival. A total of 2554 patients diagnosed with NSCLC pathologically between 01 January 2010 and 01 January 2021 were identified. After the exclusion of patients with a lack of data, unknown EGFR mutation status, no brain metastasis, and additional malignancy 336 patients were included in the study. Results: It was found that EGFR ( +) patients were more female dominant (48.6% vs 13.3% p < 0.0001) and were have less history of smoking (47.2% vs 87.1%, p < 0.0001) and were better survival (79.2% vs 92.8%). We found negativity of EGFR increased death risk by 1.700 times (95% CI 1.323–2.183, p < 0.0001) in univariate analysis and by 1.724 times (95% CI 1.251–2.377, p = 0.0001) in multivariate analysis. When overall survivals were compared estimated overall survival time of EGFR ( −) patients was 10.088 (95% CI 8.571–11.606) months and of EGFR ( +) patients was 11.829 months (95% CI 10.336–13.323) (p < 0.001). Conclusion: EGFR positivity was associated with survival. Also, survival was significantly longer in EGFR-positive patients with brain metastases diagnosed with NSCLC.
- 14 November 2024
- Published by Springer Nature in Japanese Journal of Radiology
- p. 1-12
Evaluation of nutritional parameters that may be associated with survival in patients with locally advanced non-small cell lung carcinoma receiving definitive concurrent chemoradiotherapy: retrospective study conducted in a tertiary pulmonary hospital
Sarcopenia, defined as skeletal muscle loss, is thought to be a hallmark of cancer cachexia. It has an impact on mortality, especially in cancer patients. There are also opposing views regarding the relationship between definitive concurrent chemoradiotherapy (CRT) and sarcopenia in locally advanced lung cancer. Our aim was to investigate the prognostic effect of sarcopenia in our patients with locally advanced stage III non-small cell lung cancer (NSCLC) who received definitive concurrent CRT by using many markers, and to determine the overall survival (OS). The study was designed as a retrospective cohort. 54 patients with stage III NSCLC who received definitive concurrent CRT at the Radiation Oncology Unit of Health Sciences University Izmir Dr Suat Seren Chest Diseases and Surgery Training Hospital, between January 1, 2018 and December 31, 2019, were included in the study.92% of our patients were sarcopenic with international L3-skeletal muscle index (SMI) and Psoas muscle index (PMI) threshold values. The mean OS time was 32.4 months, and the 4-year survival rate was 38.9%. While the new threshold values specific to our patient group were 26.21 for SMI and 2.94 for PMI, SMI and PMI did not indicate OS with these values. Even with the new values, most proposed criteria for sarcopenia did not indicate OS. However, low BMI (≤21.30), low serum albumin (≤4.24 mg/dl) and low visceral fat tissue area (≤37) in univariate analysis, and low visceral fat tissue area (≤37) in multivariate analysis indicated OS. OS was poor in patients with low fat tissue area. In patients with stage III NSCLC who received definitive concurrent CRT, low visceral fat tissue area (≤37) indicated OS, rather than SMI, PMI and other sarcopenia indices.
- 14 November 2024
- Published by Springer Nature in Japanese Journal of Radiology
- p. 1-12
Evaluation of nutritional parameters that may be associated with survival in patients with locally advanced non-small cell lung carcinoma receiving definitive concurrent chemoradiotherapy: retrospective study conducted in a tertiary pulmonary hospital
Sarcopenia, defined as skeletal muscle loss, is thought to be a hallmark of cancer cachexia. It has an impact on mortality, especially in cancer patients. There are also opposing views regarding the relationship between definitive concurrent chemoradiotherapy (CRT) and sarcopenia in locally advanced lung cancer. Our aim was to investigate the prognostic effect of sarcopenia in our patients with locally advanced stage III non-small cell lung cancer (NSCLC) who received definitive concurrent CRT by using many markers, and to determine the overall survival (OS). The study was designed as a retrospective cohort. 54 patients with stage III NSCLC who received definitive concurrent CRT at the Radiation Oncology Unit of Health Sciences University Izmir Dr Suat Seren Chest Diseases and Surgery Training Hospital, between January 1, 2018 and December 31, 2019, were included in the study.92% of our patients were sarcopenic with international L3-skeletal muscle index (SMI) and Psoas muscle index (PMI) threshold values. The mean OS time was 32.4 months, and the 4-year survival rate was 38.9%. While the new threshold values specific to our patient group were 26.21 for SMI and 2.94 for PMI, SMI and PMI did not indicate OS with these values. Even with the new values, most proposed criteria for sarcopenia did not indicate OS. However, low BMI (≤21.30), low serum albumin (≤4.24 mg/dl) and low visceral fat tissue area (≤37) in univariate analysis, and low visceral fat tissue area (≤37) in multivariate analysis indicated OS. OS was poor in patients with low fat tissue area. In patients with stage III NSCLC who received definitive concurrent CRT, low visceral fat tissue area (≤37) indicated OS, rather than SMI, PMI and other sarcopenia indices.
- Open Access
- 10 January 2024
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 25 (1) , 17-25
Factors Associated with Increasing Costs in Severe Chronic Obstructive Pulmonary Disease Exacerbation: Turkish Thoracic Society Chronic Obstructive Pulmonary Disease Assembly
COPD,severe exacerbation,costs,discharge,antibiotic,nutrition,pulmonary rehabilitation
- 10 January 2024
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 25 (1) , 17-25
Open AccessFactors Associated with Increasing Costs in Severe Chronic Obstructive Pulmonary Disease Exacerbation: Turkish Thoracic Society Chronic Obstructive Pulmonary Disease Assembly
COPD,severe exacerbation,costs,discharge,antibiotic,nutrition,pulmonary rehabilitation
- 1 November 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (11) , 1025-1031
How does chronic obstructive pulmonary disease affect the survival of patients with stage 4 lung cancer?
Background Lung cancer risk is increased in COPD. However, it is not clear how COPD affects the course of lung cancer. Aim To determine whether the overall survival of stage 4 lung cancer patients differ in various COPD stages. Study design: A cross-sectional retrospective study. Methods We screened lung cancer patients with ICD code: C34 and included stage 4 lung cancer patients with histological diagnosis and pulmonary function tests at admission in the study. Demographic data, stages, metastasis sites and number of metastases, performance status, pulmonary function tests, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages, arterial blood gasses and treatment methods were recorded on a standardised database. We checked their dates of death from national database. Data were evaluated with SPSS programme version 18. Results: Out of 900 patients, 146 patients had stage 4 disease at the time of diagnosis and, 127 patients had COPD. There was a significant difference between survivals of stage 4 cancer patients with different COPD stages. As COPD stage increased, overall survival worsened (P = 0.037). Factors affecting survival were bone metastasis (P = 0.01, OR = 1.72), liver metastasis (P = 0.04, OR = 1.87), brain metastasis (P = 0.001, OR = 2.6), having N 2-3 disease (P = 0.01, OR = 1.79) and GOLD 4 COPD (P = 0.01, OR = 2.28). Conclusion As COPD becomes more severe, overall survival rates of stage 4 patients worsen. Bone metastasis, liver metastasis, brain metastasis, having N2-3 disease and GOLD 4 COPD worsen the overall survival.
- 1 November 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (11) , 1025-1031
How does chronic obstructive pulmonary disease affect the survival of patients with stage 4 lung cancer?
Background Lung cancer risk is increased in COPD. However, it is not clear how COPD affects the course of lung cancer. Aim To determine whether the overall survival of stage 4 lung cancer patients differ in various COPD stages. Study design: A cross-sectional retrospective study. Methods We screened lung cancer patients with ICD code: C34 and included stage 4 lung cancer patients with histological diagnosis and pulmonary function tests at admission in the study. Demographic data, stages, metastasis sites and number of metastases, performance status, pulmonary function tests, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages, arterial blood gasses and treatment methods were recorded on a standardised database. We checked their dates of death from national database. Data were evaluated with SPSS programme version 18. Results: Out of 900 patients, 146 patients had stage 4 disease at the time of diagnosis and, 127 patients had COPD. There was a significant difference between survivals of stage 4 cancer patients with different COPD stages. As COPD stage increased, overall survival worsened (P = 0.037). Factors affecting survival were bone metastasis (P = 0.01, OR = 1.72), liver metastasis (P = 0.04, OR = 1.87), brain metastasis (P = 0.001, OR = 2.6), having N 2-3 disease (P = 0.01, OR = 1.79) and GOLD 4 COPD (P = 0.01, OR = 2.28). Conclusion As COPD becomes more severe, overall survival rates of stage 4 patients worsen. Bone metastasis, liver metastasis, brain metastasis, having N2-3 disease and GOLD 4 COPD worsen the overall survival.
- 25 September 2019
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 21 (3) , 150-155
Characteristics of Patients with Large-Cell Neuroendocrine Carcinoma of the Lung
Turkthoracj, Turkish Thoracic Journal
- 25 September 2019
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 21 (3) , 150-155
Characteristics of Patients with Large-Cell Neuroendocrine Carcinoma of the Lung
Turkthoracj, Turkish Thoracic Journal
- 18 October 2018
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 19 (4) , 182-186
Duration of Stay of Patients with Community-Acquired Pneumonia in Influenza Season
Turkthoracj, Turkish Thoracic Journal
- 18 October 2018
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 19 (4) , 182-186
Duration of Stay of Patients with Community-Acquired Pneumonia in Influenza Season
Turkthoracj, Turkish Thoracic Journal